Kairos Pharma
KAPA
5 hedge funds and large institutions have $618K invested in Kairos Pharma in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
783% more capital invested
Capital invested by funds: $70K → $618K (+$548K)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
150% more funds holding
Funds holding: 2 → 5 (+3)
2.81% more ownership
Funds ownership: 0.35% → 3.16% (+2.8%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UB
UMB Bank
Kansas City,
Missouri
|
+$569K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$16.6K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$29.2K |
| 2 |
HF
HRT Financial
New York
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
UB
1
UMB Bank
Kansas City,
Missouri
| $564K | +$569K | +371,115 | New |
|
|
VF
2
Virtu Financial
New York
| $21K | -$29.2K | -19,055 | -58% |
|
|
3
Citadel Advisors
Miami,
Florida
| $16.7K | +$16.8K | +10,969 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $16.5K | +$16.6K | +10,845 | New |
|
|
5
Bank of America
Charlotte,
North Carolina
| $20 | +$20 | +13 | New |
|
|
HF
6
HRT Financial
New York
| – | -$19K | -12,609 | Closed |
|
KAPA Hedge Fund Activity: Q4 2024 in Review
5 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q4 2024, worth a combined $618K — up 783% from $70K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KAPA positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UMB Bank, opening a new position worth an estimated $569K. The largest seller was Virtu Financial, cutting an estimated $29.2K.
- 5 institutional investors held Kairos Pharma (KAPA) as of Q4 2024, up from 2 in Q3 2024.
- Funds reported $618K of Kairos Pharma stock for Q4 2024, up 783% quarter-over-quarter.
- 4 funds opened new Kairos Pharma positions in Q4 2024 and 1 closed out, a net change of +3 holders.
- The largest Kairos Pharma buyer in Q4 2024 was UMB Bank, an estimated $569K added.
- The largest Kairos Pharma seller in Q4 2024 was Virtu Financial, an estimated $29.2K sold.
Based on aggregated 13F filings for Q4 2024.